To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical trial NCT03544281 · COMPLETED
Trial details
- NCT number
- NCT03544281
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-20
- Primary completion
- 2023-02-28
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.